In DLBCL, the pathway was previously reported to be recurrently inactivated (54), but in multiple myeloma and myeloproliferative disorders, TGF-β exerted pro-tumor activity by inhibiting host tumor immune surveillance. This evidence concerns the gene TGFB1 and neoplasm.